12:00 AM
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Dako, Roche deal

Dako and Roche's Genentech Inc. unit will collaborate on U.S. regulatory submissions for Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for Genentech's trastuzumab emtansine ( T-DM1) in patients with advanced HER2-positive breast cancer. Roche and Genentech plan to submit an MAA and BLA in 2H12 for T-DM1 to treat HER2-positive...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >